Outcomes of allogeneic hematopoietic stem cell transplantation in R/R DLBCL patients with failure of CAR-T therapy

IF 9.4 1区医学 Q1 HEMATOLOGY

Experimental Hematology & Oncology Pub Date : 2024-01-16 DOI:10.1186/s40164-024-00473-y

Mengya Cong, Sicheng Ai, Liqing Kang, Mao Jin, Ying Zhu, Caixia Li, Zhengming Jin, Lei Yu, Depei Wu, Haiwen Huang

引用次数: 0

Abstract

From October 2017 to June 2022, we retrospectively report outcomes of R/R DLBCL patients with failure of CAR-T therapy, then receiving allo-HSCT. Among 10 patients, 5 were males and 5 females, with a median age of 43.5 (27–52) years. All patients were diagnosed refractory/relapsed diffuse large B cell lymphoma. The median time from CAR-T treatment to transplantation was 84.5 (31–370) days. The median follow-up was 21 (3–69) months. 5/10 patients attained CR and 1/10 patient attained PR during the follow up. The objective response rate (ORR) was 60%. The 1-year overall survival (OS) and progression-free survival (PFS) were 70% and 40%, respectively. At the time of the analysis, 6 patients were still living. During the follow up, four patients have died and the causes were disease relapses and progressions (2 patients), acute renal failure (1 patient), severe pulmonary infection (1 patient). Non-relapse was 20.0%.

查看原文本刊更多论文

CAR-T 疗法失败的 R/R DLBCL 患者接受异基因造血干细胞移植的结果

2017年10月至2022年6月，我们回顾性报告了CAR-T疗法失败后接受allo-HSCT的R/R DLBCL患者的治疗结果。10名患者中，男性5人，女性5人，中位年龄为43.5（27-52）岁。所有患者均被诊断为难治性/复发性弥漫大B细胞淋巴瘤。从CAR-T治疗到移植的中位时间为84.5（31-370）天。中位随访时间为 21（3-69）个月。随访期间，5/10 的患者达到 CR，1/10 的患者达到 PR。客观反应率（ORR）为60%。1年总生存期（OS）和无进展生存期（PFS）分别为70%和40%。在进行分析时，仍有 6 名患者存活。在随访期间，有4名患者死亡，死亡原因分别是疾病复发和进展（2名患者）、急性肾功能衰竭（1名患者）、严重肺部感染（1名患者）。未复发率为 20.0%。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Experimental Hematology & Oncology Medicine-Oncology

CiteScore

12.60

自引率

7.30%

发文量

审稿时长

6 weeks

期刊介绍： Experimental Hematology & Oncology is an open access journal that encompasses all aspects of hematology and oncology with an emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with 'negative' results and basic science studies with provocative findings. Experimental Hematology & Oncology publishes original work, hypothesis, commentaries and timely reviews. With open access and rapid turnaround time from submission to publication, the journal strives to be a hub for disseminating new knowledge and discussing controversial topics for both basic scientists and busy clinicians in the closely related fields of hematology and oncology.